What 'delaying knee replacement' actually means

For many patients with knee osteoarthritis, the question is straightforward: can an injection put off a knee replacement? The honest answer is yes — but with an important qualification. Evidence supports a meaningful delay measured in months to years, not an indefinite alternative to surgery.

No injection currently available alters the underlying structural course of osteoarthritis. Cartilage does not regenerate, and joint-space loss does not reverse. What injections can do is reduce pain, ease inflammation, and support function well enough that surgery can be deferred — sometimes considerably. Clinicians describe this as 'bridging': buying time for continued physiotherapy, weight management, rehabilitation, or simply reaching a more practical point in life to undergo an operation.

The bridge concept only holds where there is something left to bridge. In mild-to-moderate osteoarthritis with viable joint space remaining, injections have a meaningful role. In end-stage, bone-on-bone disease, the structural basis for a useful response is largely absent, and surgery tends to become the more realistic path regardless of how many injections are tried.

Whether to bridge or proceed is an individual decision shaped by pain severity, functional limitation, age, general health, and personal preference — not by injection availability alone. The evidence that follows helps frame what is realistically achievable.

Hyaluronic acid: where the delay evidence is strongest

One large US health claims study of 182,022 patients who went on to have total knee replacement (TKR) offers the sharpest numbers available. Median time from diagnosis to surgery was 114 days for patients who never received hyaluronic acid (HA), rising to 484 days for those who did. Among patients completing five or more HA injection courses, the mean delay reached 3.6 years — a dose-dependent pattern that was statistically significant across all comparisons (p<0.0001). A French real-world cohort of 14,782 knee OA patients, followed between 2006 and 2013 using Cox proportional-hazards modelling, corroborated this signal: HA-treated patients had 51 additional days without surgery at the one-year mark, rising to 217 additional days at 7.5 years. A 2025 evidence summary by the American Academy of Family Physicians placed the delay at approximately 299 days compared with non-use.

The mechanism behind this durability is worth noting at this point. HA restores the viscoelastic properties of synovial fluid, modulates inflammatory mediators, and supports chondrocyte function — effects that help explain why its symptom relief tends to outlast corticosteroids beyond the first six to eight weeks post-injection, and why repeated courses appear to compound the benefit.

A complementary cost analysis found the TKA expenditure spike arrived at around 16–17 months post-diagnosis in HA users compared with 5–6 months in non-users — a financial footprint consistent with the delay signal. HA itself accounted for only 3% of the $6.6 billion in total knee OA treatment costs across the cohort, suggesting the broader savings from deferred surgery substantially outweigh injection expenditure.

The central limitation of these large studies is their observational design. Patients who opt for HA injections may differ from those who decline them in ways that databases cannot fully capture — healthier baseline function, stronger motivation for conservative management, or earlier-stage disease. Some of the apparent delay may reflect these pre-existing differences rather than a direct treatment effect.

Guideline bodies have reached different conclusions from the same evidence. AAOS and NICE withhold routine endorsement of HA; ESCEO and OARSI support its conditional use. A 2025 umbrella review rated its efficacy as 'moderate' for pain and function in early-to-moderate OA. The disagreement reflects genuine uncertainty, not a settled debate — though none of the major bodies dispute that the delay signal exists in real-world data.

Corticosteroids: short-term flare control and a critical timing rule

Corticosteroids occupy a narrower but clearly defined role in the bridging toolkit. Their strength is acute flare management: a well-timed injection can reduce pain and swelling reliably within days, with effects typically lasting six to twelve weeks. That window is useful for getting through a difficult period or maintaining participation in physiotherapy — but it does not constitute a sustained bridging strategy in the way that hyaluronic acid courses can.

The reason corticosteroids are not well-suited to long-term use is a recognised safety signal. Repeated injections over time carry evidence of accelerating cartilage breakdown rather than preserving it, which works against the fundamental aim of keeping the joint functional for as long as possible.

The most clinically important finding for anyone approaching surgery, however, concerns timing. A 2022 meta-analysis drawing on eight studies and more than 200,000 patients found that intra-articular injections given within three months of total knee arthroplasty significantly raised postoperative infection risk (RR 1.26; 95% CI 1.18–1.35). Injections given four to six months before surgery showed no statistically significant excess risk, and those given seven to twelve months prior showed none at all. A separate analysis of 76,090 TKA patients confirmed elevated risk even among those injected within two weeks of their operation.

The practical implication is straightforward: a three-month gap between a corticosteroid injection and elective knee replacement is a firm planning constraint, not a loose preference. Any patient who has had a recent injection and is now scheduling surgery should flag the timing to their surgical team — it may affect the operative date.

PRP and newer agents: what the current evidence supports

Platelet-rich plasma (PRP) offers perhaps the most intriguing signal among newer injectables, though it remains some distance from the evidence scale that HA has accumulated. A 2020 retrospective survival analysis found PRP injections were associated with a meaningful delay in the need for knee arthroplasty. A French cost-effectiveness model added economic context: compared with HA, PRP showed an incremental cost-effectiveness ratio of €760 per QALY in moderate-to-severe knee OA — well within the €10,000 willingness-to-pay threshold used in that analysis. The gap lies in scale and study design: no large randomised controlled trial has yet measured time-to-TKR as a primary endpoint for PRP, and the delay association rests on retrospective observation, where differences in patient selection and baseline disease severity can inflate apparent benefit. Research is ongoing, and PRP's bridging potential may become clearer as larger prospective data mature.

Polyacrylamide hydrogel (Arthrosamid®) and stem-cell therapies occupy a more experimental position still. An open-label study of 49 patients examined a single 6 mL ultrasound-guided hydrogel injection and reported sustained clinical improvement — a durability signal that distinguishes it from agents requiring repeated dosing, and the most concrete indication currently available that a single-injection approach may offer a longer functional window. The cohort size, however, is too small to characterise its bridging role reliably. Stem-cell approaches remain similarly exploratory for this specific question. Both categories sit at a 'continued investigation' threshold rather than established clinical use. Like all injections in the bridging context, any gains these agents may produce lie in symptom control and functional improvement — the underlying osteoarthritis process is not reversed.

Who is most likely to benefit from injection bridging

Bridging works best when there is still something to bridge. Clinicians assessing suitability look beyond reported pain intensity to radiological grade and measured joint space on weight-bearing imaging. A patient with measurable residual joint space offers the structural conditions for injectables to act on — at end-stage disease, where joint space has effectively collapsed, the biological mechanisms underpinning HA and PRP lose their substrate, and the risk-benefit calculation shifts firmly towards surgical planning rather than further injection cycles.

Symptom pattern also guides agent selection. Predominantly inflammatory presentations — swelling, warmth, acute pain spikes — tend to respond well to corticosteroid bridging for short-term control. Patients whose goal is sustained functional delay over months to years are better matched to HA or PRP, where the evidence for durable benefit is stronger.

A 2024 systematic review of five RCTs (552 participants) found that injections outperformed physiotherapy for short-term pain relief, yet physiotherapy produced better long-term functional results. Combination therapy — injections alongside a structured exercise programme — yielded the strongest outcomes overall. The practical implication is that injections are most useful when embedded within a broader management plan; exercise, weight management, and physiotherapy remain the evidence base for long-term OA control alongside any injection programme, not alternatives to it.

For patients advised to improve surgical candidacy before operating — by reducing body weight, optimising glycaemic control, or managing cardiovascular risk — a structured injection programme can sustain function during that preparation phase. The clinical logic is that reducing operative risk and buying managed function are distinct, legitimate goals: extra months of tolerable mobility can translate directly into a safer surgical outcome when the time comes.

How injection therapy fits into a realistic delay plan

Translating the evidence into a workable plan means thinking in structured phases rather than isolated injections. The strongest delay signal from HA research comes not from a single course but from repeated treatment — the dose-dependent pattern showing five or more courses correlating with a mean 3.6-year delay suggests that planning a series of treatments, reviewed at each stage, is more rational than a one-off injection followed by watchful waiting.

In practice, a sensible bridging plan weaves together HA or PRP for sustained functional support, corticosteroid for managing acute inflammatory flares, and a concurrent exercise programme — combination therapy consistently outperformed either injections or physiotherapy in isolation in the 2024 review data. Load management and weight optimisation are not adjuncts to this plan; they are part of it.

Review points should be built into any programme from the outset. The signal that the bridging window is closing tends to look less like a single event and more like a pattern: each injection course providing shorter or smaller relief, functional decline continuing between treatments, sleep or daily activity becoming increasingly compromised despite adequate pain management. When that trajectory becomes established, an earlier surgical referral — rather than another injection cycle — is the more appropriate response.

Patients in the later phases of a bridging programme should flag any recent corticosteroid injection to their surgical team; the three-month minimum gap before knee replacement is the evidence-based safety threshold, not a guideline that can safely be shortened.

The goal throughout is preserved quality of life during the delay period — not the postponement of a date on the calendar as an end in itself.

1. [1] Hyaluronic Acid Injections Are Associated with Delay of Total Knee Replacement Surgery in Patients with Knee Osteoarthritis: Evidence from a Large U.S. Health Claims Database. (2015). https://doi.org/10.1371/journal.pone.0145776 https://doi.org/10.1371/journal.pone.0145776
2. [2] Platelet-rich plasma injections delay the need for knee arthroplasty: a retrospective study and survival analysis. (2020). https://doi.org/10.1007/s00264-020-04669-9 https://doi.org/10.1007/s00264-020-04669-9
3. [3] Knee OA management: A cost-effectiveness analysis of platelet-rich-plasma versus hyaluronic acid for the intra-articular treatment of knee OA in France. (2018). https://doi.org/10.4172/1758-4272.1000202 https://doi.org/10.4172/1758-4272.1000202
4. [4] Maximizing Knee OA Treatment: A Comparative Look at Physiotherapy and Injections. (2024). https://doi.org/10.3390/jpm14111077 https://doi.org/10.3390/jpm14111077
5. [5] Knee OA cost comparison for hyaluronic acid and knee arthroplasty. (2020). https://doi.org/10.1186/s13018-020-01848-7 https://doi.org/10.1186/s13018-020-01848-7
6. [6] Intra-Articular Hyaluronic Acid for Knee Osteoarthritis: A Systematic Umbrella Review. (2025). https://doi.org/10.3390/jcm14041272 https://doi.org/10.3390/jcm14041272